Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search

You are here Neurology > Staff

Gillian Slator

Ms Gillian Slator is a Research Assistant, Academic Unit Neurology, School of Medicine, TCD.  Since joining the Academic Unit of Neurology, School of Medicine, TCD in October 2012, She has been carrying out research and supporting the development of a laboratory-based translation program in neurodegeneration within the research group of Professor Orla Hardiman.
Previously, she worked as a Research Assistant on a variety of Research Projects headed by Dr Julie A. Kelly in the School of Biochemistry & Immunology, TCD, which were funded by The Wellcome Trust, Health Research Board (Ireland) and Enterprise Ireland.  Throughout this period, she was employed in a variety of techniques, as well as developing innovative research technologies. In addition, I supervised in the region of ten Senior Sophister projects.
Ms. Slator has completed various formal College training courses in radiological protection leading to her current position as the departmental radiological protection officer.  She has also undertaken various courses in the safe handling of chemical and biological materials.  Currently, within Neurology she oversees and manages the day to day working of the laboratory, as well as carrying out cutting edge research in the field of neurodegeneration.
Research Publications:
Kelly JA, Boyle NT, Cole N, Slator GR, Colivicchi MA, Stefanini C, Gobbo OL, Scalabrino GA, Ryan SM, Elamin M, Walsh C, Vajda A, Goggin MM, Campbell M, Mash DC, O'Mara SM, Brayden DJ, Callanan JJ, Tipton KF, Della Corte L, Hunter J, O'Boyle KM, Williams CH, Hardiman O. First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. Neuropharmacology. 2015 Feb;89:193-203.
Cole N, Slator G, Hardiman O, Kelly J Therapeutic Effects of a First-In-Class Thyrotropin-Releasing Hormone (TRH)-Based Lead Compound in the G93A SOD1 Transgenic Mouse Amyotrophic Lateral Sclerosis, 2011; 12(Suppl. 1): 111
Scalabrino GA, Hogan N, O’Boyle KM, Slator GR, Gregg DJ, Fitchett CM, Draper SM, Bennett GW, Hinkle PM, Bauer K, Williams CH, Tipton KF, Kelly JA. Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone, Neuropharmacology. 2007 Jun;52(7):1472-81.
Kelly JA, Scalabrino GA, Slator GR, Cullen AA, Gilmer JF, Lloyd DG, Bennett GW, Bauer K, Tipton KF, Williams CH. Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II. Biochem J. 2005 Jul 15;389(Pt 2):569-76.
Kelly, JA, Slator, GR, and O’Boyle, KM. Pharmacological distinct binding sites in rat brain for [3H]thyrotropin-releasing hormone (TRH) and [3H][3-methyl-histidine2]TRH. Biochem Pharmacol. 2002 Jun 15;63(12):2197-206.
Kelly JA, Slator GR, Tipton KF, Williams CH. and Bauer K. Kinetic Investigation of the Specificity of Thyrotropin-Releasing Hormone-Degrading Ectoenzyme for Thyrotropin -Releasing Hormone-Like peptides.  J Biol Chem. 2000 Jun 2;275(22):16746-51.
Monkstown Hospital Foundation (2014-2017) Enabling Drug Development for Motor Neuron Disease Co-PI with Professor Orla Hardiman.
Research Motor Neurone (2016-2017). Targeting neurodegeneration.